Activin and Inhibin

Lusaperidone (R107474) is an α2 adrenergic receptor antagonist with K i s of 0.13 and 0.15 nM for α2A and α2C, respectively.In VitroLusaperidone has subnanomolar affinity for α2A and α2C adrenergic receptor (K i =0.13 and 0.15 nM, respectively) and

Lusaperidone (R107474) is an α2 adrenergic receptor antagonist with K i s of 0.13 and 0.15 nM for α2A and α2C, respectively.In VitroLusaperidone has subnanomolar affinity for α2A and α2C adrenergic receptor (K i =0.13 and 0.15 nM, respectively) and

Competitive melatonin receptor antagonist.

Competitive melatonin receptor antagonist.

Competitive melatonin receptor antagonist.

LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC 50 of 24.5 µM and a K d of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivoIn VitroLV-320 (0-120 µM: SKBR3,

LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC 50 of 24.5 µM and a K d of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivoIn VitroLV-320 (0-120 µM: SKBR3,

LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC 50 of 24.5 µM and a K d of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivoIn VitroLV-320 (0-120 µM: SKBR3,

LV-320 is a potent and uncompetitive ATG4B inhibitor with an IC 50 of 24.5 µM and a K d of 16 µM. LV-320 inhibits ATG4B enzymatic activity, blocks autophagic flux in cells, and is stable, non-toxic and active in vivoIn VitroLV-320 (0-120 µM: SKBR3,

LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC 50 of 0.04 μM for L. donovani proteasome and an EC 50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain

LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC 50 of 0.04 μM for L. donovani proteasome and an EC 50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain

LXE408 is an orally active, non-competitive and kinetoplastid-selective proteasome inhibitor. LXE408 has an IC 50 of 0.04 μM for L. donovani proteasome and an EC 50 of 0.04 μM for L. donovani. LXE408 has a low propensity to cross the blood brain